3 Reasons Regeneron Stock Could Start Climbing Again

Shares of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) created a high-water mark around three and a half years ago that's still 51% above recent prices. The drugs it outlicensed to its big pharma partner, Sanofi (NYSE: SNY), succeeded in the clinic. Unfortunately, commercial launches that take baby steps when investors expect giant leaps can pressure even a biotech's stock price no matter how productive its discovery engine may be.